Novo Nordisk recently announced a pilot program to distribute Wegovy, a semaglutide injection for obesity treatment, through Brazil's public health system, the SUS. However, the two hospitals identified as partners in this initiative have publicly denied any existing formal agreement with the pharmaceutical company. Novo Nordisk claims that negotiations are ongoing, sparking questions about the actual status of these partnerships.

The proposed pilot program aims to generate clinical, economic, and social evidence regarding the effectiveness of semaglutide in treating severe obesity. This initiative is framed as a means to support equitable access to the drug for SUS patients, enhancing the healthcare policy's ability to inform public health decisions. The announcement has raised expectations for more accessible obesity treatments in Brazil's public health framework.

The denial from the hospitals raises concerns about transparency and the clarity of partnerships between public health entities and pharmaceutical companies in Brazil. As Novo Nordisk's claims about negotiations continue, the efficacy and availability of Wegovy for obesity treatment within the SUS remain uncertain, presenting challenges for health policies addressing obesity and access to necessary medications.